Skip to content

A randomized controlled trial to evaluate the efficacy and safety of zoledronic acid injection in the treatment of osteoporosis after metabolic surgery

A randomized controlled trial to evaluate the efficacy and safety of zoledronic acid injection in the treatment of osteoporosis after metabolic surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037647
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with obesity

Interventions

Experimental group:After metabolic surgery, L1-4 or femoral neck or total hip bone mineral density Z value =-2.5 SD .The experimental group started to inject zoledronic acid (Migdal).It is from Novart
control group:After metabolic surgery,L1-4 or the femoral neck or total hip bone mineral density Z value =-2.5 SD.The control group began to give mock agents: dosage form: pre-perfusion injection. Spe

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The operation was performed according to the indications of metabolic surgery in the Chinese guidelines for the prevention and treatment of type 2 diabetes. 2. Aged 18 to 45 years without menopause when signing the Informed Consent Form (ICD); 3. lumbar spine 1-4 or femoral neck or total hip bone density Z value (measured value - average bone density of the same age) / standard deviation of bone density of the same age) <= - 2.5SD. 4. Willing and able to comply with the research process of the program; 5. Be able to understand and sign the study informed consent, if it is illiterate, willing to make a handprinting on the informed consent.

Exclusion criteria

Exclusion criteria: 1. history of cardiovascular or cerebrovascular diseases; 2. uncontrolled hypertension (SBP >= 160mmhg or DBP >= 100mmhg while screening); 3. history of unstable or rapidly progressive kidney; 4. active liver disease while screening; 5. history of diagnosed mental illness or immunocompromised; 6. any type of malignant tumor (whether cured or not); 7. osteoporosis caused by other reasons or drugs. 8. history of alcoholism or drug abuse; 9. Patients known to be allergic to bisphosphonates or allergic constitution; 10. Women of childbearing age are reluctant to use contraception during the study.

Design outcomes

Primary

MeasureTime frame
Percent change in lumbar spine bone mineral density (BMD);

Secondary

MeasureTime frame
Incidence of clinical fractures;Neck of femoral, total hip BMD;Biochemical indicators of bone metabolism;

Countries

China

Contacts

Public ContactJunfeng Han

Shanghai Sixth People's Hospital

tjhjf@163.com+86 18930173817

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026